A transparent compilation of primary biomedical literature, clinical trial databases, pharmacopeial methodologies, and regulatory authorities cited across Peptides Hub Australia.
Regulatory agencies define national legal classifications, drug approval milestones, manufacturing standards, and research-grade compliance thresholds.
| Organization | Jurisdiction | Primary Role in Peptide Research |
|---|---|---|
| Therapeutic Goods Administration (TGA) | Australia | Administers the Therapeutic Goods Act 1989, regulating Australian pharmaceutical registration, laboratory licensing, and scheduling. |
| U.S. Food & Drug Administration (FDA) | United States | Oversees Investigational New Drug (IND) applications, Phase 1–3 clinical trial safety, and New Drug Approvals (NDA). |
| European Medicines Agency (EMA) | European Union | Evaluates scientific documentation, pediatric investigation plans, and centralized marketing authorizations for European territories. |
Clinical trial registries ensure public transparency for interventional clinical studies, recording patient enrollment numbers, trial arms, dosage escalations, and completion timelines.
| Registry | Relevant Trial Identifiers | Focus Area |
|---|---|---|
| ClinicalTrials.gov (NIH) | Global registry tracking retatrutide Phase 3 trials (TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, TRIUMPH-4) and Phase 2 dose investigations. | |
| ANZCTR Registry | ANZCTR / ACTRN | Australian and New Zealand Clinical Trials Registry for domestic biomedical and clinical pharmacology studies. |
Peer-reviewed medical journals provide independently vetted scientific data on molecular receptor binding affinities ($EC_{50}$), pharmacokinetics, and clinical outcomes.
Standardized methodologies for High-Performance Liquid Chromatography (RP-HPLC), peak area integration, and Electrospray Ionization Mass Spectrometry (ESI-MS).